{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:54:59Z","timestamp":1788875699265,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMBF Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ctrv.2022.102501","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T11:47:02Z","timestamp":1671882422000},"page":"102501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence"],"prefix":"10.1016","volume":"113","author":[{"given":"Arndt","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ochsenreither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102501_b0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM196402132700701","article-title":"Chemotherapy of Metastatic Liver Cancer by Prolonged Hepatic-Artery Infusion","volume":"270","author":"Sullivan","year":"1964","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102501_b0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.1965.03080090021005","article-title":"Selective concentration of anticancer drugs in the liver: hepatic-artery infusion and induced hepatic outflow block","volume":"191","author":"Rousselot","year":"1965","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102501_b0015","first-page":"3062","article-title":"A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00270-013-0826-5","article-title":"Evaluation of Delcath Systems' Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion","volume":"37","author":"Moeslein","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102501_b0025","first-page":"1539","article-title":"Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver","volume":"82","author":"Vahrmeijer","year":"2000","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0030","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdn032","article-title":"Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients","volume":"19","author":"van Iersel","year":"2008","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol \/ ESMO"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102501_b0035","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102501_b0040","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/02713683.2017.1297997","article-title":"Uveal melanoma risk factors: a systematic review of meta-analyses","volume":"42","author":"Nayman","year":"2017","journal-title":"Curr Eye Res"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41572-022-00339-9","article-title":"Author correction: uveal melanoma","volume":"8","author":"Jager","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102501_b0050","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1158\/1078-0432.CCR-21-0567","article-title":"Therapeutic escape in galphaq-mutant uveal melanoma: it's a FAK","volume":"27","author":"Harbour","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5S","key":"10.1016\/j.ctrv.2022.102501_b0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.6004\/jnccn.2018.0042","article-title":"New NCCN guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma","volume":"16","author":"Barker","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102501_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235926","article-title":"The clinical feature and treatment outcome of ocular melanoma: a 34-year experience in a tertiary referral center","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102501_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092557","article-title":"Treatment of metastatic uveal melanoma: systematic review","volume":"12","author":"Rodriguez-Vidal","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.133","article-title":"Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives","volume":"2","author":"Buder","year":"2013","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102501_b0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102501_b0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.08.005","article-title":"How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma","volume":"103","author":"Steeb","year":"2018","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102501_b0085","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0095","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Database issue","key":"10.1016\/j.ctrv.2022.102501_b0100","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102501_b0105","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010117","article-title":"An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis","volume":"12","author":"Seedor","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0040-1720948","article-title":"Locoregional therapies for the treatment of uveal melanoma hepatic metastases","volume":"37","author":"Gonsalves","year":"2020","journal-title":"Semin Interv Radiol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jfo.2015.04.005","article-title":"Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients","volume":"38","author":"Piperno-Neumann","year":"2015","journal-title":"J Fr Ophtalmol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0125","doi-asserted-by":"crossref","first-page":"e0120181","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol \/ ESMO"},{"issue":"1129","key":"10.1016\/j.ctrv.2022.102501_b0135","doi-asserted-by":"crossref","first-page":"20210200","DOI":"10.1259\/bjr.20210200","article-title":"Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review","volume":"95","author":"Alexander","year":"2022","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010118","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience","volume":"14","author":"Dewald","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102501_b0150","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","article-title":"Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies","volume":"23","author":"Pingpank","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102501_b0155","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1091581818811306","article-title":"Percutaneous hepatic perfusion with filtered melphalan for localized treatment of metastatic hepatic disease: a risk assessment","volume":"37","author":"McEwan","year":"2018","journal-title":"Int J Toxicol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102501_b0165","doi-asserted-by":"crossref","first-page":"9510-","DOI":"10.1200\/JCO.2021.39.15_suppl.9510","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: preliminary results of FOCUS (PHP-OCM-301\/301A) phase III trial","volume":"39","author":"Zager","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102501_b0170","doi-asserted-by":"crossref","first-page":"9510-","DOI":"10.1200\/JCO.2022.40.16_suppl.9510","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102501_b0175","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102501_b0180","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","article-title":"Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors","volume":"143","author":"Kirstein","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102501_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma","volume":"32","author":"Modi","year":"2022","journal-title":"Melanoma Res"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102501_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184726","article-title":"Meta-analysis of isolated hepatic perfusion and percutaneous hepatic perfusion as a treatment for uveal melanoma liver metastases","volume":"13","author":"Bethlehem","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2022.102501_b0195","doi-asserted-by":"crossref","DOI":"10.1007\/s00270-022-03225-9","article-title":"Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis","author":"Tong","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102501_b0200","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0205","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0210","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2022.102501_b0215","doi-asserted-by":"crossref","unstructured":"Vogel A, Martinelli E, clinicalguidelines@esmo.org EGCEa, Committee EG. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol: Official J Eur Soc Med Oncol \/ ESMO 2021;32(6):801\u20135.","DOI":"10.1016\/j.annonc.2021.02.014"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102501_b0220","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2022.102501_b0225","unstructured":"ILCA. ILCA Systemic Therapy Guidance. Available from: <https:\/\/ilca-online.org\/wp-content\/uploads\/2020\/06\/Systemic-therapy-guidelines-V1.2.pdf>."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0235","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol \/ ESMO"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1159\/000508724","article-title":"Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma","volume":"9","author":"Ueshima","year":"2020","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0245","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102501_b0250","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102501_b0255","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000518257","article-title":"The role of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"66","author":"Li","year":"2021","journal-title":"Chemotherapy"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102501_b0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102501_b0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gutjnl-2017-314138","article-title":"FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin for advanced hepatocellular carcinoma","volume":"67","author":"Lyu","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102501_b0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00270-021-02983-2","article-title":"Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers","volume":"45","author":"Veelken","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2022.102501_b0275","doi-asserted-by":"crossref","first-page":"378-","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2022.102501_b0280","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"4C","key":"10.1016\/j.ctrv.2022.102501_b0285","first-page":"3009","article-title":"Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study","volume":"27","author":"Mambrini","year":"2007","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0290","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0b013e3181d2709a","article-title":"Phase I\/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301)","volume":"34","author":"Inaba","year":"2011","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102501_b0295","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010070","article-title":"A new option for the treatment of intrahepatic cholangiocarcinoma: percutaneous hepatic perfusion with CHEMOSAT delivery system","volume":"10","author":"Ferrucci","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102501_b0305","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0034-1366081","article-title":"Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers","volume":"186","author":"Vogl","year":"2014","journal-title":"Rofo"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102501_b0310","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","article-title":"Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival","volume":"29","author":"Marquardt","year":"2019","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102501_b0315","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1470-2045(19)30798-3","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Bridgewater","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102501_b0320","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102501_b0325","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamasurg.2019.1694","article-title":"Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review","volume":"154","author":"Datta","year":"2019","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102501_b0330","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/bjs.4308","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver","volume":"90","author":"Rothbarth","year":"2003","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102501_b0335","doi-asserted-by":"crossref","first-page":"e0261939","DOI":"10.1371\/journal.pone.0261939","article-title":"Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer","volume":"17","author":"Meijer","year":"2022","journal-title":"PLoS One"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:12Z","timestamp":1759656492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":67,"alternative-id":["S0305737222001773"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102501","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102501"}}